<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03637634</url>
  </required_header>
  <id_info>
    <org_study_id>Childhood NPC</org_study_id>
    <nct_id>NCT03637634</nct_id>
  </id_info>
  <brief_title>The Children and Adolescents Nasopharyngeal Carcinoma Survivor Study</brief_title>
  <acronym>CANPCSS</acronym>
  <official_title>The Children and Adolescents Nasopharyngeal Carcinoma Survivor Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hai-Qiang Mai,MD,PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Jinan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Shantou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhanjiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Zhongshan Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dongguan People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fifth Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangmen Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yuebei People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Guizhou Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Cancer Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangxi Provincial Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Children and Adolescents Nasopharyngeal Carcinoma Survivor Study will investigate the
      long-term effects of nasopharyngeal carcinoma (NPC) and its associated therapies. A
      prospective and retrospective cohort study will be conducted through a multi-institutional
      collaboration. This project will study children and adolescents exposed to specific
      therapeutic modalities, including radiation, chemotherapy, and/or surgery, who are at
      increased risk of late-occurring adverse health outcomes. A group of sibling controls will be
      identified and data collected for comparison purposes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will focus on the following objectives:

        -  Characterize survivors' health with respect to disease- and treatment-related factors.

        -  Investigate the consequences of various intensities of exposure to chemotherapy and/or
           radiation on health outcomes (e.g., cardiovascular, reproductive, second cancers, etcâ€¦).

        -  Compare the mortality experience of survivors with the general population.

        -  Characterize the health-related behaviors, patterns of medical care, and medical
           follow-up needs of survivors.

        -  Describe patterns of familial aggregation of cancer, including known (and variations of)
           cancer family syndromes.

        -  Collect and store biologic samples (saliva, blood, second tumor tissue) to correlate
           with health outcomes and use for future research.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2035</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>5 years</time_frame>
    <description>The OS was defined as the duration from the date of random assignment to the date of death from any cause or censored at the date of the last follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress-free survival(PFS)</measure>
    <time_frame>5 years</time_frame>
    <description>Progress-free survival is calculated from the date of randomization to the date of the first progress at any site or death from any cause or censored at the date of the last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional failure-free survival(LRFS)</measure>
    <time_frame>5 years</time_frame>
    <description>The LRFS is evaluated and calculated from the date of random assignment until the day of first locoregional relapse or until the date of the last follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-free survival(DMFS)</measure>
    <time_frame>5 years</time_frame>
    <description>The DMFS is evaluated and calculated from the date of random assignment until the day of first distant metastases or until the date of the last follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term toxic effects assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0)</measure>
    <time_frame>3 months</time_frame>
    <description>The shortterm toxic effects were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Long-term toxicities</measure>
    <time_frame>Through study completion, an average of half year</time_frame>
    <description>QoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTCQLQ-C30)</description>
  </other_outcome>
  <other_outcome>
    <measure>Long-term toxicities</measure>
    <time_frame>Through study completion, an average of half year</time_frame>
    <description>EORTC quality of life questionnaire(QLQ) Head and Neck</description>
  </other_outcome>
  <other_outcome>
    <measure>Long-term toxicities</measure>
    <time_frame>Through study completion, an average of half year</time_frame>
    <description>Late Effects Normal Tissue Task Force-Subjective, Objective, Management and Analytic (LENT-SOMA) scoring systems</description>
  </other_outcome>
  <other_outcome>
    <measure>Growth</measure>
    <time_frame>Through study completion, an average of half year</time_frame>
    <description>Patients will be monitored for height(in metre)</description>
  </other_outcome>
  <other_outcome>
    <measure>Growth</measure>
    <time_frame>Through study completion, an average of half year</time_frame>
    <description>Patients will be monitored for weight(in kilogram)</description>
  </other_outcome>
  <other_outcome>
    <measure>Growth</measure>
    <time_frame>Through study completion, an average of half year</time_frame>
    <description>Patients will be monitored for BMI(in kg/m^2)</description>
  </other_outcome>
  <other_outcome>
    <measure>Sex Development</measure>
    <time_frame>Through study completion, an average of half year</time_frame>
    <description>secondary sex characteristic survey</description>
  </other_outcome>
  <other_outcome>
    <measure>Sex Development</measure>
    <time_frame>Through study completion, an average of half year</time_frame>
    <description>sex hormone(estrogen,testosterone) levels(in nmol/L).</description>
  </other_outcome>
  <other_outcome>
    <measure>Intelligence Development</measure>
    <time_frame>Through study completion, an average of half year</time_frame>
    <description>Intelligence quotient by Stanford-Binet test</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>NPC Patients</condition>
  <arm_group>
    <arm_group_label>NPC survivors</arm_group_label>
    <description>Survivors of NPC, diagnosed under 21 years of age, between 1990 and 2030. This project will study children and young adults exposed to specific therapeutic modalities, including radiation, chemotherapy, and/or surgery, for an increased risk of late-occurring events associated with excess mortality and morbidity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sibling Controls</arm_group_label>
    <description>A group of sibling controls will be identified to provide: (1) the ability to make direct comparisons with the survivors, (2) data on outcomes in a non-cancer population, and (3) additional comparison group to determine the consistency of findings between data sources.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, saliva and tumor specimens
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        NPC patients under 21 years old and their siblings
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients or their siblings must be informed of the investigational nature of this
             study and give written informed consent.

               -  Patients with histologically confirmed non-keratinizing nasopharyngeal carcinoma
                  (including differentiated type and undifferentiated type, WHO II or III) before
                  age 21 years at one of participating centers.

        Exclusion Criteria:

          -  Already involved in other blind clinical trial.

          -  The information of tumour response evaluation and survival data cannot be obtained.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hai Mai, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haiqiang Mai, Dr</last_name>
    <phone>86-20-8734-3643</phone>
    <email>maihq@mail.sysu.edu.cn</email>
  </overall_contact>
  <reference>
    <citation>Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005 Jun 11-17;365(9476):2041-54. Review.</citation>
    <PMID>15950718</PMID>
  </reference>
  <reference>
    <citation>Levine PH, Connelly RR, Easton JM. Demographic patterns for nasopharyngeal carcinoma in the United States. Int J Cancer. 1980 Dec 15;26(6):741-8.</citation>
    <PMID>7216543</PMID>
  </reference>
  <reference>
    <citation>Ingersoll L, Woo SY, Donaldson S, Giesler J, Maor MH, Goffinet D, Cangir A, Goepfert H, Oswald MJ, Peters LJ. Nasopharyngeal carcinoma in the young: a combined M.D. Anderson and Stanford experience. Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):881-7.</citation>
    <PMID>2120164</PMID>
  </reference>
  <reference>
    <citation>Downing NL, Wolden S, Wong P, Petrik DW, Hara W, Le QT. Comparison of treatment results between adult and juvenile nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1064-70. doi: 10.1016/j.ijrobp.2008.12.030. Epub 2009 Mar 26.</citation>
    <PMID>19327901</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 3, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <last_update_submitted>August 26, 2018</last_update_submitted>
  <last_update_submitted_qc>August 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hai-Qiang Mai,MD,PhD</investigator_full_name>
    <investigator_title>Hai-Qiang Mai</investigator_title>
  </responsible_party>
  <keyword>children and adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

